Nutrastar Releases Record Third Quarter 2013 Results

New Post Public Reply Private Reply Replies (0) Message Board
MoneyMaker
Nutrastar Releases Record Third Quarter 2013 Results

HARBIN, China, Nov. 13, 2013 /PRNewswire-FirstCall/ -- Nutrastar International Inc. (OTCQB: NUIN; "Nutrastar" or the "Company"), a leading producer and supplier of premium branded consumer products, including commercially cultivated Cordyceps Militaris ("Cordyceps"), health beverages and organic and specialty foods, today announced its financial results for the three and nine months ended September 30, 2013.

Three Months Ended September 30, 2013 Financial Highlights

Net revenue increased 44.4% to $10.94 million, up from $7.57 million in the three months ended September 30, 2012.
Gross profit increased 46% to $8.78 million, up from $6.01 million in the comparable third quarter 2012
Gross margin was 80.3% compared with 79.4% in the third quarter 2012.
Net income was $5.78 million, up 54.4% from $3.74 million recorded in Q3 2012.
Basic and diluted EPS were $0.36 and $0.34, respectively, with 15.92 million basic and 17.06 million diluted shares outstanding.
Nine Months Ended September 30, 2013 Financial Highlights

Net revenue increased 23.5% to $30.22 million, compared to $24.47 million in the nine months ended September 30, 2012.
Gross profit increased 26.3% to $23.56 million, up from $18.66 million in the comparable 2012 nine month period.
Gross margin was 78.0%, compared to 76.3% in the first nine months of 2012.
Net income was $15.16 million, up 30.7% from $11.6 million in the nine months ended September 30, 2012.
Basic and diluted EPS were $0.94 and $0.89, respectively, with 15.88 million basic and 17.02 million diluted shares outstanding.
Management Commentary

"In the three and nine months ended September 20, 2013, our numbers reflected continued and significant growth in sales, gross profit, and income. Gross margin further improved to 80.3% in the third quarter thanks to our increased capacity as well as an attractive product mix comprised mainly of our high margin commercially cultivated Cordyceps. Cordyceps, functional health beverage and organic specialty food sales specifically were up 48.5%, 39.7% and 5.9%, respectively, in the third quarter of 2013 versus the comparable 2012 quarter. Increases in sales this quarter came from increased capacity as well as company-led marketing initiatives," stated, Ms. Lianyun Han, CEO of Nutrastar.

Ms. Han continued, "With the production means necessary to expand our market, we are focused on further extending our brand awareness and product offering to better and more comprehensively serve our customers. Prior launched marketing campaigns are working to promote the health benefits of our premium consumer products, especially our on-the-go functional health beverage and instant soluble drink. We also began testing sales of our instant soluble drink at the Bao Feng specialty drug store in Harbin for an initial trial period of up to six months that began this month. Bao Feng is a direct consumer specialty drug store that has approximately 1,000 stores nationwide. Depending on how sales do in the trial store, this may or may not be a channel  for us moving forward. On the new product front, we have started developing Cordyceps capsules and tablets, designed to complement our current premium consumer product offering and cater to our everyday customer looking for an on-the-go health supplement similar to other vitamin-type supplements. It's estimated that the product development process for both capsules and tablets will take approximately 12 – 18 months to complete."

In closing, Ms. Han stated, "With consumer demand for our premium products remaining strong and persistent, particularly among the wealthier and aging population, we are quite confident in our ability to meet our full year revenue guidance and continue to grow thereafter. We look forward to updating our shareholders and the investment community on our progress in these areas and more in the time ahead."

Request for Call with Management

Investors are invited to schedule a call with Nutrastar's management team. For those investors who are interested in speaking with management, please contact American Capital Ventures at +1-305-918-7000 to schedule.

For more information regarding Nutrastar's financial performance during the quarter ended September 30, 2013, please refer to the Quarterly Report Form 10-Q to be filed with the Securities and Exchange Commission on or about November 13, 2013.

About Nutrastar International Inc.

Nutrastar is a China based leading producer and supplier of premium branded consumer products including commercially cultivated Cordyceps Militaris, functional health beverages as well as specialty and organic foods. Cordyceps Militaris is one of the most highly regarded herbal nutrients in Traditional Chinese Medicine. The Company is headquartered in Harbin, capital of Heilongjiang Province, with 330 employees, including 21 in R&D, and 149 in sales and marketing. The products of Nutrastar are sold throughout China via a sales and distribution network that covers more than 10 provinces. More information may be found at http://www.nutrastarintl.com/ or e-mail: ir@nutrastarintl.com

Make sure you are first to receive timely up-to-date information on Nutrastar. Sign up for Nutrastar's email news alert system today at: http://www.nutrastarintl.com/alerts

Safe Harbor Statement

This news release contains "forward-looking statements" relating to the business of Nutrastar International Inc., its subsidiaries and other affiliate companies.  All statements, other than statements of historical fact included herein are "forward-looking statements" including statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts.  These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions.  These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the Company with the Securities and Exchange Commission. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors.  You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Other than as required under the securities laws, the Company does not assume a duty to update any forward-looking statements to reflect events or circumstances after the date hereof.

For more information, please contact:? 

Howard Gostfrand
American Capital Ventures
Tel:  +1-305-918-7000
Email: info@amcapventures.com

NUTRASTAR INTERNATIONAL INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME

(Unaudited)

(AMOUNTS EXPRESSED IN US DOLLARS)









For the Three Months



For the Nine Months



Ended September 30,



Ended September 30,



2013



2012



2013



2012

NET REVENUE

$

10,935,950


$

7,572,443


$

30,221,420


$

24,468,889

Cost of goods sold


(2,159,255)



(1,559,180)



(6,662,959)



(5,809,842)

GROSS PROFIT


8,776,695



6,013,263



23,558,461



18,659,047

Selling expenses


(435,920)



(350,426)



(1,340,176)



(1,198,434)

General and administrative expenses


(588,375)



(551,348)



(1,877,642)



(1,880,591)

Income from operations


7,752,400



5,111,489



20,340,643



15,580,022

Other income (expenses):












   Interest income


72,633



59,957



235,122



193,839

   Foreign exchange differences


21,517



(3,440)



47,974



(14,607)

   Change in fair value of warrants


-



(25,915)



173



114,845

   Total other income


94,150



30,602



283,269



294,077

Income before income taxes


7,846,550



5,142,091



20,623,912



15,874,099

Provision for income taxes


(2,066,105)



(1,397,501)



(5,465,974)



(4,278,897)

NET INCOME


5,780,445



3,744,590



15,157,938



11,595,202

OTHER COMPREHENSIVE INCOME:












   Foreign currency translation adjustments


521,176



(199,602)



2,150,468



(486,711)

COMPREHENSIVE INCOME

$

6,301,621


$

3,544,988


$

17,308, 406


$

11,108,491

Earnings per share:












   Basic

$

0.36


$

0.24


$

0.94


$

0.74

   Diluted

$

0.34


$

0.23


$

0.89


$

0.70

Weighted average number of shares 
      outstanding:












   Basic


15,919,261



15,402,196



15,882,507



15,376,476

   Diluted


17,060,119



16,532,296



17,018,122



16,515,212

 

 



NUTRASTAR INTERNATIONAL INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(AMOUNTS EXPRESSED IN US DOLLARS)





For the Nine Months Ended


September 30,



2013



2012

CASH FLOWS FROM OPERATING ACTIVITIES:






Net income

$

15,157,938


$

11,595,202

Adjustments to reconcile net income to cash provided by operating activities:






   Change in fair value of warrants


(173)



(114,845)

   Depreciation and amortization


1,101,320



926,272

   Share-based compensation expense – employees


142,653



313,262

   Share-based compensation expense – non employees


4,767



-

(Increase) decrease in assets:






         Accounts receivable


(6,347)



(1,110)

         Inventories


(645,094)



(321,613)

         Prepayments and other receivables


127,818



109,625

Increase (decrease) in liabilities:






         Accounts payable





(6,323)

         Other payables and accruals


421,181



277,756

         Taxes payable


(489,557)



(737,396)

     Net cash provided by operating activities


15,814,506



12,040,830







CASH FLOWS FROM INVESTING ACTIVITIES:






Refund of prepayments for cold studios


-



1,266,424

Purchase of property, plant and equipment


-



(15,903)

     Net cash provided by investing activities


-



1,250,521







CASH FLOWS FROM FINANCING ACTIVITIES:






Decrease in restricted cash


-



4,170

Purchase of common stock


-



(69,214)

(Repayment to) advance from related party


(36,106)



82,674

     Net cash (used in) provided by financing activities


(36,106)



17,630







Foreign currency translation adjustment


1,855,165



(390,824)







INCREASE IN CASH AND CASH EQUIVALENTS


17,633,565



12,918,157

CASH AND CASH EQUIVALENTS, at the beginning of the period


75,526,533



54,556,329







CASH AND CASH EQUIVALENTS, at the end of the period

$

93,160,098


$

67,474,486







NON-CASH TRANSACTIONS






Preferred stock and dividend converted into common stock

$

-


$

995,587

Preferred stock dividend payable


170,601



218,685

Share-based payment to officers and directors under equity incentive plan


142,653



313,262

Share-based payment to non-employees


4,767



-

SUPPLEMENTAL DISCLOSURE INFORMATION






Income taxes paid

$

5,605,361


$

4,773,432



 

NUTRASTAR INTERNATIONAL INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(AMOUNTS EXPRESSED IN US DOLLARS)









September 30,



December 31,



2013



2012



(Unaudited)




ASSETS






CURRENT ASSETS






 Cash and cash equivalents

$

93,160,098


$

75,526,533

 Accounts receivable


89,737



81,497

 Inventories


1,638,953



965,251

 Prepayments and other receivables


1,222,077



1,321,726

   Total current assets


96,110,865



77,895,007

OTHER ASSETS






 Intangible assets, net


1,220,574



1,552,022

 Property, plant and equipment, net


15,601,555



15,991,060







   Total assets

$

112,932,994


$

95,438,089







LIABILITIES AND STOCKHOLDERS' EQUITY












CURRENT LIABILITIES






 Other payables and accruals

$

1,938,935


$

1,481,198

 Taxes payable


2,552,924



2,981,136

 Due to a related party


159,763



150,036

 Preferred stock dividend payable


699,129



528,528

 Warrants liabilities


-



173

   Total current liabilities


5,350,751



5,141,071

   Total liabilities


5,350,751



5,141,071

COMMITMENTS AND CONTINGENCIES (Note 17)






STOCKHOLDERS' EQUITY






Preferred Stock, $0.001 par value, 1,000,000 shares authorized, 113,010
      shares issued and outstanding; aggregate liquidation preference amount:
      $3,164,280 and $3,164,280, plus accrued but unpaid dividend of
      $699,129 and $528,528, at September 30, 2013 and December 31, 2012,
      respectively


2,577,324



2,577,324







Common stock, $0.001 par value, 190,000,000 shares authorized,
      15,907,381 shares issued; 15,953,826 shares and 15,863,826 shares  
      outstanding at September 30, 2013 and December 31, 2012, respectively


15,998



15,908







 Additional paid-in capital


19,176,916



19,029,586

 Statutory reserves


4,966,457



4,960,023

 Treasury stock, at cost, 43,555 shares as of September 30, 2013 and
      December 31, 2012


(78,767)



(78,767)

 Retained earnings


73,306,835



58,325,932

 Accumulated other comprehensive income


7,617,480



5,467,012

   Total stockholders' equity


107,582,243



90,297,018







   Total liabilities and stockholders' equity

$

112,932,994


$

95,438,089

SOURCE Nutrastar International Inc.


Copyright 2013 PR Newswire
Scroll down for more posts ▼

Top 10 Most Recent News Articles

UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 12

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 5

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading

Top 5 Most Recently Viewed Articles

Taseko Mines Earnings: Missed Estimates or Surprising Upside?

Updated Category News Views 144

Taseko Mines (AMEX:TGB) is set to drop its quarterly earnings report on February 18, 2026, and traders are already buzzing about it. The whispers in the hallways suggest a glimmer of hope, with analysts eyeing an earnings per share (EPS) of $0.08—a target that could shift market sentiments depending on how it lands. The last quarter's performance still stings; Taseko...

Continue Reading
Magnet Biomedicine Enhances Research with Simplicis's Ledger™

Updated Category News Views 173

Magnet Biomedicine Partners with Simplicis's Ledger™ Platform Magnet Biomedicine, a pioneering biotechnology firm focused on advancing molecular glue discovery, has recently chosen Simplicis's Ledger™ platform following a thorough assessment of leading alternatives. This decision reflects a commitment to enhancing research operations and optimizing compound management...

Continue Reading
Forecasting Asset Appreciation: Bitcoin and Gold's Potential Rise

Updated Category News Views 114

Understanding Market Dynamics Under Uncertain Political Landscapes In the world of finance, significant political changes can lead to substantial shifts in market dynamics. Recent insights from JPMorgan analysts suggest that a victory for Donald Trump could lead to a spike in both Bitcoin and gold prices. This projection is rooted in growing interest from retail investors...

Continue Reading
Apple and Google Forge a Powerful AI Partnership for Future

Updated Category News Views 73

Apple and Google's Exciting AI Collaboration With the excitement surrounding artificial intelligence expected to surge into 2026, tech enthusiasts and market analysts alike are keenly observing the landscape. The anticipation is mounting as companies evaluate their AI capabilities, looking to distinguish true leaders from those merely riding the wave of hype. In a...

Continue Reading
Podcasting Industry Set to Hit $114 Billion With New Trends

Updated Category News Views 241

Explosive Growth in the Podcasting Market Podcasting continues to gain massive traction, with predictions estimating the market will skyrocket from USD 31.49 billion now to an impressive USD 114.48 billion by 2030. This remarkable growth, with a compound annual growth rate (CAGR) of 29.45%, is driven by several innovative trends reshaping the media landscape....

Continue Reading